Nuvation Bio Inc Dossier - Source-backed chat

Nuvation Bio Inc

NUVBNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.34

Intrinsic Value $3.23median of 2 methodsbased on filings through 30 Jun 2026

Market Price $5.56Price as of 1 Oct 2026

OvervaluedIntrinsic value is 42% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2B

Enterprise Value $1.9B

Shares Outstanding 349.9M diluted

Next Earnings Date4 Jan 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nuvation Bio Inc. has successfully transitioned from a clinical-stage biotech into a commercial-stage oncology company following the FDA approval of its lead asset, IBTROZI (taletrectinib), in June 2025. The company's investment profile is anchored by two highly promising assets: IBTROZI, a next-generation ROS1 inhibitor showing best-in-class efficacy and a favorable safety profile in ROS1+ NSCLC, and safusidenib, a brain-penetrant mutant IDH1 inhibitor in Phase 3 development for gliomas. With a robust cash position of $533.7 million as of March 31, 2026, and positive operating cash flow achieved in Q1 2026, Nuvation Bio is well-capitalized to execute its commercial launch and advance its pipeline without near-term dilutive financing.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$13.11

High · most bullish analyst$21.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0015%

IBTROZI commercial adoption slows due to intense competition from established players (BMS/repotrectinib) and new market entrants (Nuvalent/zidesamtinib). Safusidenib's Phase 3 SIGMA trial fails to meet its primary endpoints or experiences significant delays, and preclinical assets in the DDC platform fail to transition successfully to clinical development, leading to a higher cash burn rate and eventual dilutive financing.

Base CaseCentral scenario

$13.1160%

Matches the consensus mean

IBTROZI continues its steady commercial ramp, maintaining a pace of ~200 new patient starts per quarter with a growing shift toward first-line (TKI-naïve) usage, driving strong 'revenue stacking' dynamics. Safusidenib advances on track toward its Phase 3 SIGMA readout in 2027-2028, and the company receives regulatory milestones from its global partnerships (such as Eisai in Europe). The company remains well-funded, avoiding equity dilution.

Bull CaseUpside scenario

$21.0025%

IBTROZI achieves rapid market penetration, capturing over 50% of the first-line ROS1+ NSCLC market due to its superior efficacy (90% ORR, ~50-month median DOR) and lower neurological toxicity compared to competitors like repotrectinib. Concurrently, safusidenib secures accelerated FDA approval in Grade 3 oligodendroglioma based on strong Phase 2/3 ORR data, and the drug-drug conjugate (DDC) platform yields highly promising clinical candidates, triggering significant upward valuation re-rating and potential M&A interest.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

IBTROZI demonstrates potentially best-in-class clinical efficacy with an 89-90% ORR, 50-month median DOR, and 46-month median PFS in TKI-naïve ROS1+ NSCLC patients.
Favorable safety profile of IBTROZI with significantly lower rates of neurological adverse events (e.g., dizziness) compared to competing next-generation TKIs.
Strong balance sheet with $533.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a multi-year runway.
Strategic global partnerships, including a lucrative licensing agreement with Eisai for European rights, which brought in a $58.7 million upfront payment in Q1 2026.
Late-stage pipeline optionality with safusidenib, a brain-penetrant IDH1 inhibitor targeting a large underserved glioma market.

Key Investment Risks

Highly competitive ROS1+ NSCLC market with established therapies from Pfizer, Roche, and BMS, alongside upcoming next-generation competitors like Nuvalent's zidesamtinib.
Clinical and regulatory risks associated with the Phase 3 development of safusidenib and the early-stage drug-drug conjugate (DDC) platform.
Concentration risk as the company's near-term commercial success is entirely dependent on the market uptake of a single product (IBTROZI).
Potential long-term financing needs if commercial revenues do not scale fast enough to offset heavy R&D and SG&A expenditures.

Thesis Invalidation Triggers

A sharp decline in quarterly new patient starts or net product revenue for IBTROZI.
Failure of safusidenib to meet its primary endpoints in the Phase 3 SIGMA trial or negative regulatory feedback on its accelerated approval pathway.
Safety signals or elevated liver enzyme concerns leading to restrictive FDA labeling or clinical holds on IBTROZI or safusidenib.
Rapid market share capture by Nuvalent's zidesamtinib following its potential FDA approval in late 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.